<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:31:47Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2361763" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2361763</identifier><datestamp>2009-09-10</datestamp><setSpec>brjcancer</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="other">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2361763</article-id>
      <article-id pub-id-type="pmcid">PMC2361763</article-id>
      <article-id pub-id-type="pmc-uid">2361763</article-id>
      <article-id pub-id-type="pmid">15841082</article-id>
      <article-id pub-id-type="pii">6602547</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6602547</article-id>
      <article-id pub-id-type="pmid">15841082</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Molecular Diagnostics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Somatic and germline mutation in <italic>GRIM-19</italic>, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (HÃ¼rthle cell) tumours of the thyroid</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>MÃ¡ximo</surname>
            <given-names>V</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Botelho</surname>
            <given-names>T</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capela</surname>
            <given-names>J</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soares</surname>
            <given-names>P</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>J</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taveira</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amaro</surname>
            <given-names>T</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>A P</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Preto</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harach</surname>
            <given-names>H R</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Williams</surname>
            <given-names>D</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sobrinho-SimÃµes</surname>
            <given-names>M</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="aff" rid="aff8">8</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal</aff>
      <aff id="aff2"><label>2</label>Department of Surgery, Hospital SÃ£o JoÃ£o, Porto, Portugal</aff>
      <aff id="aff3"><label>3</label>Department of Pathology, Medical Faculty of Porto, Porto, Portugal</aff>
      <aff id="aff4"><label>4</label>Department of Pathology, Portuguese Oncology Institute, Porto, Portugal</aff>
      <aff id="aff5"><label>5</label>Department of Endocrinology, Portuguese Oncology Institute, Porto, Portugal</aff>
      <aff id="aff6"><label>6</label>Pathology Service, âDr A OnÃ£tivia' Hospital, Salta, Argentina</aff>
      <aff id="aff7"><label>7</label>Strangeways Research Laboratory, University of Cambridge, Cambridge, UK</aff>
      <aff id="aff8"><label>8</label>Department of Pathology, Hospital SÃ£o JoÃ£o, Porto, Portugal</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:ssimoes@ipatimup.pt">ssimoes@ipatimup.pt</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>04</month>
        <year>2005</year>
      </pub-date>
      <pub-date pub-type="collection">
        <day>17</day>
        <month>05</month>
        <year>2005</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>23</day>
        <month>05</month>
        <year>2005</year>
      </pub-date>
      <volume>92</volume>
      <issue>10</issue>
      <fpage>1892</fpage>
      <lpage>1898</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>11</month>
          <year>2004</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>02</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>02</month>
          <year>2005</year>
        </date>
      </history>
      <copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement>
      <copyright-year>2005</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <abstract>
        <p>Oxyphil or HÃ¼rthle cell tumours of the thyroid are characterised by their consistent excessive number of mitochondria. A recently discovered gene, <italic>GRIM-19</italic> has been found to fulfil two roles within the cell: as a member of the interferon-<italic>Î²</italic> and retinoic acid-induced pathway of cell death, and as part of the mitochondrial Complex I assembly. In addition, a gene predisposing to thyroid tumours with cell oxyphilia (<italic>TCO</italic>) has been mapped to chromosome 19p13.2 in one family. A cluster of genes involved in mitochondrial metabolism occurs in this region; one of these is <italic>GRIM-19.</italic> We have searched for <italic>GRIM-19</italic> mutations in a series of 52 thyroid tumours. Somatic missense mutations in <italic>GRIM-19</italic> were detected in three of 20 sporadic HÃ¼rthle cell carcinomas. A germline mutation was detected in a HÃ¼rthle cell papillary carcinoma arising in a thyroid with multiple HÃ¼rthle cell nodules. No mutations were detected in any of the 20 non-HÃ¼rthle cell carcinomas tested, nor in any of 96 blood donor samples. In one of the sporadic HÃ¼rthle cell papillary carcinomas positive for <italic>GRIM-19</italic> mutation, we have also detected a ret/PTC-1 rearrangement. No <italic>GRIM-19</italic> mutations were detected in any of the six cases of known familial HÃ¼rthle cell tumour tested, so that our results do not support the identification of <italic>GRIM-19</italic> as the <italic>TCO</italic> gene. The <italic>GRIM-19</italic> mutations we have detected are the first nuclear gene mutations specific to HÃ¼rthle cell tumours to be reported to date; we propose that such mutations can be involved in the genesis of sporadic or familial HÃ¼rthle cell tumours through the dual function of GRIM-19 in mitochondrial metabolism and cell death.</p>
      </abstract>
      <kwd-group>
        <kwd>thyroid cancer</kwd>
        <kwd>familial thyroid carcinoma</kwd>
        <kwd>HÃ¼rthle cell tumours</kwd>
        <kwd>
          <italic>GRIM-19</italic>
        </kwd>
        <kwd>mitochondrial proteins</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Oxyphil or HÃ¼rthle cell thyroid tumours constitute an unusual form of neoplasm composed of cells with a great increase in mitochondrial number, corresponding morphologically to their voluminous, granular, eosinophilic cytoplasm (<xref ref-type="other" rid="bib21">Hamperl, 1962</xref>; <xref ref-type="other" rid="bib33">Nesland <italic>et al</italic>, 1985</xref>; <xref ref-type="other" rid="bib39">Sobrinho-SimÃµes <italic>et al</italic>, 1985</xref>; <xref ref-type="other" rid="bib35">Rosai <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib38">Sobrinho-SimÃµes, 1995</xref>). The excessive numbers of mitochondria are found in all tumour cells, both in adenomas and in carcinomas. Large deletions of mitochondrial DNA (mtDNA), as well as somatic mutations of some mitochondrial genes are the hallmark of HÃ¼rthle cell tumours (<xref ref-type="other" rid="bib31">MÃ¡ximo and Sobrinho-SimÃµes, 2000a</xref>; <xref ref-type="other" rid="bib30">MÃ¡ximo <italic>et al</italic>, 2002</xref>). HÃ¼rthle cell tumours are multiple in a proportion of cases; the multiple tumours more often occur in younger patients than the solitary tumours, suggesting a germline defect (<xref ref-type="other" rid="bib25">Katoh <italic>et al</italic>, 1998</xref>). Dominant inheritance has only rarely been reported; a study of one pedigree with familial HÃ¼rthle cell tumours found a linkage to chromosome 19p13.2, but the identity and function of this <italic>TCO</italic> gene remains unknown (<xref ref-type="other" rid="bib6">Canzian <italic>et al</italic>, 1998</xref>).</p>
    <p>Recently, a novel gene, <italic>GRIM-19</italic>, has been identified. It is one of several genes associated with retinoid-interferon-induced mortality (<italic>GRIM</italic>) that have been reported in the literature (<xref ref-type="other" rid="bib22">Hofmann <italic>et al</italic>, 1998</xref>). <italic>GRIM-19</italic> is a cell death regulatory gene that promotes apoptosis, is a negative regulator of cell growth and is also involved in mitochondrial metabolism (<xref ref-type="other" rid="bib1">Angell <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib29">Lufei <italic>et al</italic>, 2003</xref>), it has been mapped to human chromosome 19p13.2 (<xref ref-type="other" rid="bib9">Chidambaram <italic>et al</italic>, 2000</xref>). <italic>GRIM-19</italic> is the human homologue of the bovine subunit of the mitochondrial NADH:ubiquinone oxireductase complex (Complex I) of the mitochondrial respiratory chain (MRC) (<xref ref-type="other" rid="bib16">Fearnley <italic>et al</italic>, 2001</xref>). Like cytochrome <italic>c</italic>, which has a role in the induction of the cell's apoptotic programme and in the MRC (<xref ref-type="other" rid="bib28">Liu <italic>et al</italic>, 1996</xref>), and endonuclease G, which is released from mitochondria during apoptosis and subsequently translocated to the nucleus (<xref ref-type="other" rid="bib27">Li <italic>et al</italic>, 2001</xref>), GRIM-19 has been found to fulfil two roles within the cell: as a member of the interferon-<italic>Î²</italic> and retinoic acid-induced pathway of cell death (<xref ref-type="other" rid="bib1">Angell <italic>et al</italic>, 2000</xref>), and as part of the mitochondrial Complex I assembly (<xref ref-type="other" rid="bib16">Fearnley <italic>et al</italic>, 2001</xref>). These two seemingly disparate functions may be linked, through the involvement of mitochondria in apoptotic cell death.</p>
    <p>The functional importance of GRIM-19 has been recently highlighted by knockout experiments. <xref ref-type="other" rid="bib23">Huang <italic>et al</italic> (2004)</xref> generated mice deficient in <italic>GRIM-19</italic> by gene targeting, and showed that homologous deletion of <italic>GRIM-19</italic> causes embryonic lethality at embryonic day 9.5. Interestingly, <italic>GRIM-19</italic><sup>â/â</sup> blastocysts display abnormal mitochondrial structure, morphology and cellular distribution (<xref ref-type="other" rid="bib23">Huang <italic>et al</italic>, 2004</xref>).</p>
    <p>The consistent linkage of increased mitochondrial number and increased cell growth that characterises HÃ¼rthle cell tumours suggests that one gene could be involved in both features. The dual role of GRIM-19 in apoptosis and mitochondrial biogenesis makes it a good candidate for being a gene involved in HÃ¼rthle cell tumorigenesis. Its localisation to the same region as the <italic>TCO</italic> gene (chromosome 19p13.2) also suggested that it could be involved in the aetiopathogenesis of familial HÃ¼rthle cell tumours. We have therefore searched for <italic>GRIM-19</italic> mutations in HÃ¼rthle cell tumours, and in controls.</p>
    <p><xref ref-type="other" rid="bib29">Lufei <italic>et al</italic> (2003)</xref> and <xref ref-type="other" rid="bib44">Zhang <italic>et al</italic> (2003)</xref> have demonstrated that the major role of GRIM-19 in control of cell growth is exerted through STAT3, a transcription factor known to be inhibited by GRIM-19 binding (<xref ref-type="other" rid="bib29">Lufei <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib44">Zhang <italic>et al</italic>, 2003</xref>). Signal transducers and activators of transcription (STATs) are a family of latent cytoplasmic transcription factors that are activated after recruitment by the cytokine membrane receptors and subsequent phosphorylation. STAT proteins form homo- or heterodimers by reciprocal interactions between SH2 domains and phosphorylated tyrosine residues, translocate to the nucleus, bind to DNA and regulate their target gene expression (<xref ref-type="other" rid="bib12">Darnell <italic>et al</italic>, 1994</xref>). It was suggested that activation of STAT3 may contribute to the loss of cell growth control, therefore leading to carcinogenesis (<xref ref-type="other" rid="bib19">Grandis <italic>et al</italic>, 2000</xref>), by inducing elevated expression of genes involved in controlling fundamental cellular processes such as <italic>cyclin D1</italic> (<xref ref-type="other" rid="bib18">Fukada <italic>et al</italic>, 1998</xref>), <italic>c-Myc</italic> (<xref ref-type="other" rid="bib3">Bromberg <italic>et al</italic>, 1999</xref>), <italic>p21</italic><sup><italic>WAF1/CIP1</italic></sup> (<xref ref-type="other" rid="bib10">Chin <italic>et al</italic>, 1996</xref>), as well as <italic>VEGF</italic> (<xref ref-type="other" rid="bib34">Niu <italic>et al</italic>, 2002</xref>) and <italic>ICAM1</italic> (<xref ref-type="other" rid="bib4">Caldenhoven <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib5">Cantwell <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib24">Hwang <italic>et al</italic>, 2003</xref>). Owing to the difficulty in studying the functional impairment of mutated <italic>GRIM</italic>-19 directly in formalin-fixed tissue, we have investigated the levels of expression of <italic>ICAM1</italic> in our series in an attempt to provide indirect evidence of the putative loss of function of GRIM-19.</p>
    <p>Since ret/PTC rearrangements and <italic>B-RAF</italic> mutations are particularly prevalent in papillary carcinomas regardless of whether or not they have HÃ¼rthle cell features (<xref ref-type="other" rid="bib20">Grieco <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib36">Soares <italic>et al</italic>, 1998</xref>, <xref ref-type="other" rid="bib37">2003</xref>; <xref ref-type="other" rid="bib40">Sugg <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib11">Cohen <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib26">Kimura <italic>et al</italic>, 2003</xref>), we have also searched for the aforementioned genetic alterations in HÃ¼rthle cell carcinomas with <italic>GRIM-19</italic> mutations.</p>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <sec>
        <title>Material</title>
        <p>We studied 26 sporadic HÃ¼rthle cell tumours (five adenomas, 11 cases of the HÃ¼rthle cell variant of follicular carcinoma and 10 cases of the HÃ¼rthle cell variant of papillary carcinoma, all showing papillary carcinoma nuclear features), six carcinomas from two families with HÃ¼rthle cell tumours, 20 cases of non-HÃ¼rthle cell carcinomas (10 follicular carcinomas and 10 papillary carcinomas) (<xref ref-type="other" rid="bib14">DeLellis <italic>et al</italic>, 2004</xref>) and 96 blood donor samples. In one of the families (four cases) there was known linkage to chromosome 19p13.2. The study was approved by the Ethical Committees of all Institutions involved and informed consent was obtained from all individuals studied.</p>
      </sec>
      <sec>
        <title>DNA extraction</title>
        <p>DNA was extracted from microdissected frozen and/or paraffin-embedded tissue pairs (tumour and adjacent ânormal' thyroid) using the NucleoSpinÂ® Tissue Kit (Macherey-Nagel, DÃ¼ren, Germany). DNA from blood of some patients and from blood donor samples was also extracted using the same procedure.</p>
      </sec>
      <sec>
        <title>Screening of <italic>GRIM-19</italic> mutations</title>
        <p>We searched for mutations in all five exons of <italic>GRIM-19</italic> including intronic boundaries (primer sequences shown in <xref rid="tbl1" ref-type="table">Table 1</xref>) using PCR/Automated sequencing. All PCR amplifications were performed in a 25â<italic>Î¼</italic>l volume containing 200â<italic>Î¼</italic><sc>M</sc> of each dNTP, 12.5âpmol of each of the forward and reverse primers, 50âm<sc>M</sc> KCl, 10âm<sc>M</sc> Tris-HCl (pH 9.0), 1.5âm<sc>M</sc> MgCl<sub>2</sub> and 1âU of <italic>Taq</italic> DNA polymerase (Amersham Pharmacia Biotech). Cycling conditions were a single predenaturation step at 94Â°C for 5âmin followed by 35 cycles of denaturation at 94Â°C for 20âs, annealing at 60Â°C for 20âs and elongation at 72Â°C for 30âs, and a final incubation at 72Â°C for 5âmin. PCR products were separated by electrophoresis on 2% agarose gels and purified using the NucleoSpinÂ® Extract Kit (Macherey-Nagel, DÃ¼ren, Germany). Sequencing analysis was then carried out on purified products using the ABI Prism BigDyeâ¢ Terminator Ready Reaction Kit (Perkin-Elmer, Foster City, CA, USA) and an ABI prism 377 DNA sequencer (Perkin-Elmer). Both strands were screened using the original primers. All altered samples were subjected to an additional complete analysis.</p>
      </sec>
      <sec>
        <title>Loss of heterozygosity analysis</title>
        <p>Two markers (D19S916 and D19S413) located in the <italic>TCO</italic> (19p13.2) region were used for the loss of heterozygosity (LOH) studies with [<sup>32</sup>P]dCTP (Amersham, UK) radioactive PCR amplification. Cycling conditions were a single predenaturation step at 94Â°C for 5âmin followed by 35 cycles of denaturation at 94Â°C for 20âs, annealing at 58Â°C for 20âs and elongation at 72Â°C for 30âs, and a final incubation at 72Â°C for 5âmin. Amplicons were separated on 6% polyacrylamide denaturing gels, and exposed to X-ray film at room temperature. Loss of heterozygosity was determined by comparing the intensity of the alleles in heterozygosity samples of matched tumour and normal DNA. Loss of heterozygosity analysis was performed in all cases of sporadic (<italic>n</italic>=26) HÃ¼rthle cell tumours.</p>
      </sec>
      <sec>
        <title>Evaluation of the expression of <italic>ICAM1</italic></title>
        <p>To obtain an indirect evaluation of the functional activity of GRIM-19, we calculated the relative expression of <italic>ICAM1</italic> (tumour tissue <italic>vs</italic> normal adjacent tissue) in 26 HÃ¼rthle cell tumours with and without <italic>GRIM-19</italic> mutations. <italic>ICAM1</italic> is known to be upregulated by STAT3, a transcription factor whose function is inhibited by GRIM-19 protein (<xref ref-type="other" rid="bib29">Lufei <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib44">Zhang <italic>et al</italic>, 2003</xref>). <italic>ICAM1</italic> expression was performed as follows. For each sample 1.0â<italic>Î¼</italic>g of RNA was reverse transcribed in a reaction volume of 20â<italic>Î¼</italic>l in the presence of 4âm<sc>M</sc> dNTP, 1.0âUâ<italic>Î¼</italic>l<sup>â1</sup> RNase inhibitor, 2.5â<italic>Î¼</italic><sc>M</sc> random primer P (dN)<sub>6</sub> and 10âUâ<italic>Î¼</italic>l<sup>â1</sup> M-MLV reverse transcriptase. Reverse-transcribed cDNAs (0.25â<italic>Î¼</italic>g) from normal and neoplastic tissues were used to coamplify the housekeeping gene â <italic>glyceraldehyde-3-phosphate dehydrogenase</italic> (<italic>GAPDH</italic>) (primers GAPDHF â tgt cag tgg tgg gac ctg acc t â and GAPDHR â cac cct gtt gct gta gcc aaa tt; amplicon: 254âbp), and the differentially expressed gene â <italic>ICAM1</italic> gene (primers ICAM1F â caa ccg gaa ggt gta tga act ga â and ICAM1R â tgg cag cgt agg gta agg ttc tt; amplicon: 186âbp). Cycling conditions were a single predenaturation step at 94âÂ°C for 5âmin followed by 24 cycles of denaturation at 94âÂ°C for 20âs, annealing at 58âÂ°C for 20âs and elongation at 72âÂ°C for 20âs, and a final incubation at 72âÂ°C for 5âmin. The PCR products were separated in an agarose gel (2%), and stained with ethidium bromide. The intensity of the fluorescence was automatically measured and integrated using the <italic>Multi-Analyst â version 1.1 â</italic> software in the BIO RAD Gel DOC 1000 (<italic>BIO RAD</italic>, CA, USA). All the quantitations were performed in triplicate.</p>
      </sec>
      <sec>
        <title>Screening of ret/PTC rearrangements</title>
        <p>RNA extracted from paraffin-embedded tumour tissue of patients who presented <italic>GRIM-19</italic> mutations was used for detecting ret/PTC rearrangements following the procedures previously described (<xref ref-type="other" rid="bib17">Finn <italic>et al</italic>, 2003</xref>).</p>
      </sec>
      <sec>
        <title>Screening of <italic>B-RAF</italic> mutations</title>
        <p>To screen for <italic>B-RAF</italic> mutations, we analysed DNA extracted from paraffin-embedded tumour tissue and adjacent thyroid tissue of patients who presented GRIM-19 mutations following the procedures previously described (<xref ref-type="other" rid="bib13">Davies <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib37">Soares <italic>et al</italic>, 2003</xref>).</p>
      </sec>
      <sec>
        <title>Statistical analysis</title>
        <p>The statistical analysis of the results was performed using <italic>Ï</italic><sup>2</sup> test with the Yates correction, Fisher's exact test and Student's <italic>t</italic>-test. A <italic>P</italic>-value of &lt;0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec>
      <title>RESULTS</title>
      <sec>
        <title>Screening of <italic>GRIM-19</italic> mutations</title>
        <p>The results of GRIM-19 analysis are summarized in <xref rid="tbl2" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="fig1">Figure 1</xref>. Sequence determination of the five exons of <italic>GRIM-19</italic> in the 26 apparently sporadic HÃ¼rthle cell tumours disclosed the existence of four mutations: a C â T substitution at nucleotide 77 (exon 1) resulting in an alanine-to-valine change at residue 26 in patient 4 (HÃ¼rthle cell variant of follicular carcinoma); a G â C substitution at nucleotide 264 resulting in a lysine-to-asparagine change at residue 88 (exon 1) in patient 5 (HÃ¼rthle cell variant of papillary carcinoma with Warthin's like features) (<xref ref-type="fig" rid="fig1">Figure 1</xref>); an A â G substitution at nucleotide 247 resulting in a serine-to-glycine change at residue 83 (exon 1) in patient 6 (HÃ¼rthle cell variant of papillary carcinoma); and a G â C substitution at nucleotide 593 resulting in a arginine-to-proline change at residue 198 (exon 5) in patient 7 (HÃ¼rthle cell variant of papillary carcinoma). All mutations detected were heterozygous.</p>
        <p>In patient 5, the thyroid tissue apart from the papillary carcinoma was almost totally occupied by several nodules composed of HÃ¼rthle cells; in all samples tested, including the carcinoma, one benign nodule and the internodular normal tissue, we detected the same mutation (a G â C substitution at nucleotide 264 resulting in a lysine-to-asparagine change at residue 88). The same mutation was also detected in the peripheral blood of the patient thus confirming its germline nature. The germline nature of the mutation was confirmed by its detection in the peripheral blood of one son, aged 41 years, with no clinical or ecographic signs of thyroid disease. The mutation was not detected in the other son nor in the daughter of the patient. No mutations were detected in the adjacent normal thyroid parenchyma of the other three cases with a <italic>GRIM-19</italic> mutation (patients 4, 6 and 7), nor in any of the 42 other normal thyroid samples.</p>
        <p>We did not detect mutations in the <italic>GRIM-19</italic> gene in any of the six cases of known familial HÃ¼rthle cell tumours, in any of the 20 cases of non-HÃ¼rthle follicular and papillary carcinomas, nor in any of the 96 blood donor samples. The frequency of <italic>GRIM-19</italic> somatic mutations in the cases of HÃ¼rthle cell variant of follicular carcinoma (one out of 11; 9.1%) is not statistically different from the frequency of <italic>GRIM-19</italic> somatic mutations in cases of HÃ¼rthle cell variant of papillary carcinoma (two out of 10; 20.0%) (<italic>P</italic>=0.476); the same holds true if the case presenting the <italic>GRIM-19</italic> germline mutation is included (three out of 10; 30.0%) (<italic>P</italic>=0.223). None of the previously described polymorphisms (National Center for Biotechnology Information (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</ext-link>)) occurring at exonic regions were detected in these cases.</p>
        <p>The presence of <italic>GRIM-19</italic> mutations was not significantly associated with the age and/or gender of the patients (data not shown) nor with the histotype of the lesions other than the oxyphilia (<xref ref-type="fig" rid="fig2">Figure 2</xref>), including the presence or absence of lymphocytic thyroiditis. No significant association was also found between the presence of <italic>GRIM-19</italic> mutations and the mtDNA somatic mutations detected in a previous study (<xref ref-type="other" rid="bib30">MÃ¡ximo <italic>et al</italic>, 2002</xref>) (data not shown).</p>
      </sec>
      <sec>
        <title>Loss of heterozygosity</title>
        <p>The 26 cases in which LOH analysis was performed were informative for at least one of the two markers. We did not find LOH in any of the four HÃ¼rthle cell tumours presenting <italic>GRIM-19</italic> mutations, nor in any of the other 22 sporadic HÃ¼rthle cell tumours.</p>
      </sec>
      <sec>
        <title>Expression of <italic>ICAM1</italic></title>
        <p>The results are summarized in <xref rid="tbl3" ref-type="table">Table 3</xref>. The four tumours with mutations had significantly (<italic>P</italic>&lt;0.001) higher levels of <italic>ICAM1</italic> expression in tumoural tissue <italic>vs</italic> normal tissue (range of the ratio between the expressions of <italic>ICAM1</italic> in tumoural tissues <italic>vs</italic> normal tissue: 3.2â5.0; meanÂ±standard deviation=3.9Â±0.8) (<xref rid="tbl3" ref-type="table">Table 3</xref>) than the 22 cases without <italic>GRIM</italic>-19 mutation (range: 0.9â2.4; meanÂ±standard deviation=1.4Â±0.4). Only two cases without <italic>GRIM</italic>-19 mutation (case 12, HCPC and case 15, HCPC) showed a level of expression in tumoural tissue higher than 2 (2.3 and 2.4, respectively).</p>
      </sec>
      <sec>
        <title>Screening for RET/PTC rearrangements and <italic>B-RAF</italic> mutations</title>
        <p>The data concerning the screening for RET/PTC rearrangements and <italic>B-RAF</italic> mutations in cases displaying <italic>GRIM-19</italic> mutation are summarized in <xref rid="tbl4" ref-type="table">Table 4</xref> (case 6 â not studied for technical limitations). Ret/PTC-1 chimeric transcripts were detected in one case (Case 7); no ret/PTC-3 chimeric transcripts were detected in any case. No mutations in exons 11 and 15 of <italic>B-RAF</italic> were detected in any of the three cases from which material was available.</p>
      </sec>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>The <italic>GRIM-19</italic> mutations we have described are the first nuclear gene mutations specific to HÃ¼rthle cell tumours to be reported to date. The detection of <italic>GRIM-19</italic> mutations in four of 26 apparently sporadic HÃ¼rthle cell tumours, and their absence in 20 non-HÃ¼rthle cell tumours and 96 blood donors support the hypothesis that alterations of <italic>GRIM-19</italic> are involved in the etiopathogenesis of these tumours. Further support comes from a search for germline mutations. While these were not found in the two known families studied, one germline mutation was found in the 142 samples tested (46 normal thyroids and 96 blood donor samples), and this occurred in the only apparently sporadic tumour with multiple HÃ¼rthle cell lesions. None of the alterations detected were previously described as polymorphisms, suggesting that might affect the function of the protein, or that they are rare polymorphisms. When we compare the amino-acid sequence of the protein GRIM-19 of four different species (<italic>Homo sapiens</italic>, <italic>Bos taurus</italic>, <italic>Mus musculus</italic> and <italic>Xenopus tropicalis</italic>), two of the mutations are located in phylogenetically conserved positions (K88N, case 5 and R198P, case 7) (<xref ref-type="fig" rid="fig3">Figure 3</xref>), suggesting that they might directly affect the function of the protein. The remaining mutations (A26V, case 4 and S83G, case 6) are located in a region of human GRIM-19 protein that has no correspondence to the GRIM-19 of other species; human GRIM-19 is the largest of the four.</p>
      <p>In contrast to the absence of other documented nuclear genetic alterations, several mtDNA alterations (including large deletions and somatic mutations) have been described in sporadic HÃ¼rthle cell tumours (<xref ref-type="other" rid="bib41">Tallini <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib32">MÃ¡ximo and Sobrinho-SimÃµes, 2000b</xref>; <xref ref-type="other" rid="bib30">MÃ¡ximo <italic>et al</italic>, 2002</xref>). Curiously, most of the somatic mutations of the mtDNA on record involve genes that, like <italic>GRIM-19</italic>, code for components of Complex I of MRC (<xref ref-type="other" rid="bib43">Yeh <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib30">MÃ¡ximo <italic>et al</italic>, 2002</xref>). These genes are crucial for the oxidative phosphorylation process and consequently for the cell's energy production, and it has been suggested that mutations in genes directly or indirectly affecting mitochondrial function could be the cause of the increase in mitochondrial number in HÃ¼rthle cell tumours (<xref ref-type="other" rid="bib25">Katoh <italic>et al</italic>, 1998</xref>). It is known that a defect in the energy production machinery of the cell can lead to a secondary increase in the number of mitochondria, through a feedback mechanism (<xref ref-type="other" rid="bib2">Attardi <italic>et al</italic>, 1995</xref>). Loss of function of <italic>GRIM-19</italic> can therefore explain the mitochondrial excess typical of HÃ¼rthle cell tumours.</p>
      <p>Mutations in <italic>GRIM-19</italic> as well as affecting mitochondrial number could also influence cell growth and apoptosis. This role of <italic>GRIM-19</italic> was demonstrated using <italic>in vitro</italic> models by <xref ref-type="other" rid="bib1">Angell <italic>et al</italic> (2000)</xref>, who showed that overexpression of <italic>GRIM-19</italic> enhanced cell death in MCF-7 cells, whereas its downregulation, as well as its deletion, provided growth advantage and decreased cell death (<xref ref-type="other" rid="bib1">Angell <italic>et al</italic>, 2000</xref>). <xref ref-type="other" rid="bib23">Huang <italic>et al</italic> (2004)</xref> confirmed that GRIM-19 protein cellular localisation in various cell types is primarily mitochondrial. Furthermore, GRIM-19 is detected in the native form of mitochondrial complex I and the elimination of <italic>GRIM-19</italic> destroys the assembly and electron transfer activity of Complex I and also influences the other complexes in the mitochondrial respiratory chain (<xref ref-type="other" rid="bib23">Huang <italic>et al</italic>, 2004</xref>).</p>
      <p>In this study, <italic>GRIM-19</italic> mutations were found in 16% of HÃ¼rthle cell tumours. However <italic>GRIM-19</italic> is one of a number of genes that code for proteins involved in mitochondrial electron transport. Clusters of these genes occur at 19p13.2 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</ext-link>) and at 17p13 (<xref ref-type="other" rid="bib15">Farrand <italic>et al</italic>, 2002</xref>), both regions of the genome linked to HÃ¼rthle cell tumours. It is therefore likely that mutations in other genes with similar functions are involved in the causation of HÃ¼rthle cell tumours of the thyroid, and they should also be considered candidate genes for mitochondrial-rich tumours of other sites.</p>
      <p>The major role of GRIM-19 in control of cell growth is exerted through STAT3, a transcription factor known to be inhibited by GRIM-19 binding (<xref ref-type="other" rid="bib29">Lufei <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib44">Zhang <italic>et al</italic>, 2003</xref>). We have shown that the cases with <italic>GRIM</italic>-19 mutations display increased expression of the STAT3 regulated gene <italic>ICAM1</italic>; this finding fits with a loss of function of GRIM-19. Only two of the 22 cases without mutation in <italic>GRIM-19</italic> gene showed a slightly elevated expression of the <italic>ICAM1</italic> gene: the levels in these two cases were considerably lower (<italic>P</italic>=0.07) than those detected in four cases with mutations and may reflect alterations in pathways other than STAT3 pathway.</p>
      <p>The failure to detect LOH with the limited range of markers used does not exclude a tumorigenic role for GRIM19 mutations. <xref ref-type="other" rid="bib1">Angell <italic>et al</italic> (2000)</xref> showed that downregulation of <italic>GRIM-19</italic> was able to provide growth advantage, and cooperating mutations in one of the many other nuclear or mitochondrial genes with similar functions could also be important in this setting.</p>
      <p>Ret/PTC rearrangements were initially reported to be restricted to conventional papillary thyroid carcinomas (<xref ref-type="other" rid="bib20">Grieco <italic>et al</italic>, 1990</xref>). Later, <xref ref-type="other" rid="bib7">Cheung <italic>et al</italic> (2000)</xref> demonstrated that ret/PTC rearrangements could also be detected in cases of HÃ¼rthle cell variant of papillary carcinoma, thus supporting the assumption that ret/PTC is specific for the papillary phenotype (<xref ref-type="other" rid="bib7">Cheung <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib14">DeLellis <italic>et al</italic>, 2004</xref>). <xref ref-type="other" rid="bib8">Chiappetta <italic>et al</italic> (2002)</xref> reported the presence of the rearrangement in both benign and malignant HÃ¼rthle thyroid tumours including follicular and papillary histotypes; this finding remains to be confirmed in other series. <italic>B-RAF</italic> mutations have also been frequently detected in cases of HÃ¼rthle cell variant of papillary carcinoma (<xref ref-type="other" rid="bib42">Trovisco <italic>et al</italic>, 2004</xref>), but not in other types of HÃ¼rthle cell tumour (<xref ref-type="other" rid="bib26">Kimura <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib37">Soares <italic>et al</italic>, 2003</xref>). In order to verify if the <italic>GRIM-19</italic> mutation may cooperate with those genetic events in HÃ¼rthle cell tumours, we have searched for them in <italic>GRIM-19</italic>-positive cases. The detection of a ret/PTC-1 rearrangement in Case 7 (HÃ¼rthle cell variant of papillary carcinoma) suggests that <italic>GRIM-19</italic> mutation may serve as a predisposing alteration for the occurrence of tumours with cell oxyphilia. Other alterations, such as ret/PTC rearrangement or <italic>B-RAF</italic> mutation, may be necessary for the acquisition of the malignant phenotype, as in non-HÃ¼rthle cell papillary carcinomas (<xref ref-type="other" rid="bib20">Grieco <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib36">Soares <italic>et al</italic>, 1998</xref>, <xref ref-type="other" rid="bib37">2003</xref>; <xref ref-type="other" rid="bib40">Sugg <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib11">Cohen <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib26">Kimura <italic>et al</italic>, 2003</xref>).</p>
      <p>The autosomal dominant inheritance of HÃ¼rthle cell tumours has been described in a single family (<xref ref-type="other" rid="bib6">Canzian <italic>et al</italic>, 1998</xref>). A separate study of a large number of thyroidectomies for HÃ¼rthle cell tumours found that about 20% of cases showed multiple separate HÃ¼rthle cell tumours, and that these were significantly younger and much more often female than the solitary tumours (<xref ref-type="other" rid="bib25">Katoh <italic>et al</italic>, 1998</xref>). No mutations were detected in any of the five exons, nor in the respective intronic boundaries of <italic>GRIM-19</italic> in the six cases from two HÃ¼rthle cell tumour families. Since four of these cases belonged to the family described by <xref ref-type="other" rid="bib6">Canzian <italic>et al</italic> (1998)</xref>, our results do not support the identification of <italic>GRIM-19</italic> as the <italic>TCO</italic> gene mapped to chromosome 19p13.2 by those authors (<xref ref-type="other" rid="bib6">Canzian <italic>et al</italic>, 1998</xref>).</p>
      <p>The observation that the only germline mutation in <italic>GRIM-19</italic> found in well over 100 samples tested was in the one patient with multiple HÃ¼rthle cell tumours suggests that this gene could account for some cases with a low penetrance pattern of inheritance. The absence of identifiable lesions in the patient's son who also carried the mutated gene is not surprising in view of his younger age (41 <italic>vs</italic> 60 years) and the rarity of multiple HÃ¼rthle cell tumours in males (<xref ref-type="other" rid="bib25">Katoh <italic>et al</italic>, 1998</xref>).</p>
      <p>Proof that a particular mutation is oncogenic requires both the demonstration of its presence in tumours, and the demonstration that the mutated gene confers an oncogenic advantage. We have shown that mutations in <italic>GRIM-19</italic> are associated with a specific subtype of thyroid tumours, and each of the four mutations we found led to amino-acid substitutions. Downregulation of <italic>GRIM-19</italic> has been shown to confer a growth advantage on cells and to reduce the likelihood that they will enter apoptosis (<xref ref-type="other" rid="bib1">Angell <italic>et al</italic>, 2000</xref>). We therefore believe that <italic>GRIM-19</italic> mutations can make a significant contribution to the tumorigenic process in HÃ¼rthle cell tumours of the thyroid. Further <italic>in vitro</italic> studies are needed to demonstrate directly that the mutations we have found lead to downregulation of <italic>GRIM-19</italic> function.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Dr Pierre Levillain for having provided material from a series of four cases from a family with familial HÃ¼rthle cell tumours with linkage to chromosome 19p13.2. This study was partially supported by two PhD Grants (PRAXIS XXI/BD/21795/99 â AP, SFRH/BD/8425/2002 â JL) and by a Post-Doc Grant (SFRH/BPD/14594/2003 â VM) from the Portuguese Science and Technology Foundation (FCT),and by further funding from the same source (Project â POCT/41055/NSE/2001).</p>
    </ack>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Angell</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Kalvakolanu</surname>
              <given-names>DV</given-names>
            </name>
          </person-group>
          <article-title>Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach</article-title>
          <source>J Biol Chem</source>
          <year>2000</year>
          <volume>275</volume>
          <fpage>33416</fpage>
          <lpage>33426</lpage>
          <!--PubMed citation query: 'J Biol Chem||275|33416||bib1|'-->
          <pub-id pub-id-type="pmid">10924506</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Attardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yoneda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chomyn</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1995</year>
          <volume>1271</volume>
          <fpage>241</fpage>
          <lpage>248</lpage>
          <!--PubMed citation query: 'Biochim Biophys Acta||1271|241||bib2|'-->
          <pub-id pub-id-type="pmid">7599215</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bromberg</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Wrzeszczynska</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Devgan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pestell</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Albanese</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Darnell</surname>
              <given-names>JE</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Stat3 as an oncogene</article-title>
          <source>Cell</source>
          <year>1999</year>
          <volume>98</volume>
          <fpage>295</fpage>
          <lpage>303</lpage>
          <!--PubMed citation query: 'Cell||98|295||bib3|'-->
          <pub-id pub-id-type="pmid">10458605</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caldenhoven</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van Dijk</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Solari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Raaijmakers</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Lammers</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Koenderman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>de Groot</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription</article-title>
          <source>J Biol Chem</source>
          <year>1996</year>
          <volume>271</volume>
          <fpage>13221</fpage>
          <lpage>13227</lpage>
          <!--PubMed citation query: 'J Biol Chem||271|13221||bib4|'-->
          <pub-id pub-id-type="pmid">8675499</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantwell</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Sterneck</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1</article-title>
          <source>Mol Cell Biol</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>2108</fpage>
          <lpage>2117</lpage>
          <!--PubMed citation query: 'Mol Cell Biol||18|2108||bib5|'-->
          <pub-id pub-id-type="pmid">9528783</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canzian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Amati</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Harach</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Kraimps</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lesueur</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Barbier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Levillain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Romeo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bonneau</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2</article-title>
          <source>Am J Hum Genet</source>
          <year>1998</year>
          <volume>63</volume>
          <fpage>1743</fpage>
          <lpage>1748</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||63|1743||bib6|'-->
          <pub-id pub-id-type="pmid">9837827</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheung</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Ezzat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ramyar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Asa</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of HÃ¼rthle cell papillary thyroid carcinoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>878</fpage>
          <lpage>882</lpage>
          <!--PubMed citation query: 'J Clin Endocrinol Metab||85|878||bib7|'-->
          <pub-id pub-id-type="pmid">10690905</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiappetta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Toti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cetta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giuliano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pentimalli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Amendola</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lazzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Monaco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mazzuchelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tosi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fusco</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (HÃ¼rthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2002</year>
          <volume>87</volume>
          <fpage>364</fpage>
          <lpage>369</lpage>
          <!--PubMed citation query: 'J Clin Endocrinol Metab||87|364||bib8|'-->
          <pub-id pub-id-type="pmid">11788677</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chidambaram</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Angell</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Kalvakolanu</surname>
              <given-names>DV</given-names>
            </name>
          </person-group>
          <article-title>Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death</article-title>
          <source>J Interferon Cytokine Res</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>661</fpage>
          <lpage>665</lpage>
          <!--PubMed citation query: 'J Interferon Cytokine Res||20|661||bib9|'-->
          <pub-id pub-id-type="pmid">10926209</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chin</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Kitagawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>ZH</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>XY</given-names>
            </name>
          </person-group>
          <article-title>Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1</article-title>
          <source>Science</source>
          <year>1996</year>
          <volume>272</volume>
          <fpage>719</fpage>
          <lpage>722</lpage>
          <!--PubMed citation query: 'Science||272|719||bib10|'-->
          <pub-id pub-id-type="pmid">8614832</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mambo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Trink</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Beller</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Westra</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Ladenson</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Sidransky</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>BRAF mutation in papillary thyroid carcinoma</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2003</year>
          <volume>95</volume>
          <fpage>625</fpage>
          <lpage>627</lpage>
          <!--PubMed citation query: 'J Natl Cancer Inst||95|625||bib11|'-->
          <pub-id pub-id-type="pmid">12697856</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darnell</surname>
              <given-names>JE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title>Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</article-title>
          <source>Science</source>
          <year>1994</year>
          <volume>264</volume>
          <fpage>1415</fpage>
          <lpage>1421</lpage>
          <!--PubMed citation query: 'Science||264|1415||bib12|'-->
          <pub-id pub-id-type="pmid">8197455</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Teague</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woffendin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Garnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bottomley</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dicks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Floyd</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kosmidou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Menzies</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mould</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jayatilake</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gusterson</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hargrave</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maitland</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chenevix-Trench</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Riggins</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bigner</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cossu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Seigler</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Darrow</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the BRAF gene in human cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>417</volume>
          <fpage>949</fpage>
          <lpage>954</lpage>
          <!--PubMed citation query: 'Nature||417|949||bib13|'-->
          <pub-id pub-id-type="pmid">12068308</pub-id>
        </citation>
      </ref>
      <ref id="bib14">
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>DeLellis</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Heitz</surname>
              <given-names>PU</given-names>
            </name>
            <name>
              <surname>Eng</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title/>
          <source>World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs</source>
          <year>2004</year>
          <publisher-name>Lyon: IARC Press</publisher-name>
        </citation>
      </ref>
      <ref id="bib15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farrand</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Delahunt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XL</given-names>
            </name>
            <name>
              <surname>McIver</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Goellner</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Eberhardt</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Grebe</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2002</year>
          <volume>87</volume>
          <fpage>4715</fpage>
          <lpage>4721</lpage>
          <!--PubMed citation query: 'J Clin Endocrinol Metab||87|4715||bib15|'-->
          <pub-id pub-id-type="pmid">12364463</pub-id>
        </citation>
      </ref>
      <ref id="bib16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fearnley</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Runswick</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Hirst</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I)</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>38345</fpage>
          <lpage>38348</lpage>
          <!--PubMed citation query: 'J Biol Chem||276|38345||bib16|'-->
          <pub-id pub-id-type="pmid">11522775</pub-id>
        </citation>
      </ref>
      <ref id="bib17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finn</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>O'Leary</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sweeney</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Sheils</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>938</fpage>
          <lpage>941</lpage>
          <!--PubMed citation query: 'J Clin Endocrinol Metab||88|938||bib17|'-->
          <pub-id pub-id-type="pmid">12574236</pub-id>
        </citation>
      </ref>
      <ref id="bib18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fukada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohtani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shirogane</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hibi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition</article-title>
          <source>EMBO J</source>
          <year>1998</year>
          <volume>17</volume>
          <fpage>6670</fpage>
          <lpage>6677</lpage>
          <!--PubMed citation query: 'EMBO J||17|6670||bib18|'-->
          <pub-id pub-id-type="pmid">9822610</pub-id>
        </citation>
      </ref>
      <ref id="bib19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grandis</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Drenning</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Melhem</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Endo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis <italic>in vivo</italic></article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2000</year>
          <volume>97</volume>
          <fpage>4227</fpage>
          <lpage>4232</lpage>
          <!--PubMed citation query: 'Proc Natl Acad Sci USA||97|4227||bib19|'-->
        </citation>
      </ref>
      <ref id="bib20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grieco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berlingieri</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Melillo</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Donghi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bongarzone</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pierotti</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Della Porta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fusco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vecchio</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected <italic>in vivo</italic> in human thyroid papillary carcinomas</article-title>
          <source>Cell</source>
          <year>1990</year>
          <volume>60</volume>
          <fpage>557</fpage>
          <lpage>563</lpage>
          <!--PubMed citation query: 'Cell||60|557||bib20|'-->
          <pub-id pub-id-type="pmid">2406025</pub-id>
        </citation>
      </ref>
      <ref id="bib21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamperl</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Benign and malignant oncocytoma</article-title>
          <source>Cancer</source>
          <year>1962</year>
          <volume>15</volume>
          <fpage>1019</fpage>
          <lpage>1027</lpage>
          <!--PubMed citation query: 'Cancer||15|1019||bib21|'-->
          <pub-id pub-id-type="pmid">13904230</pub-id>
        </citation>
      </ref>
      <ref id="bib22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hofmann</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Boyanapalli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Weihua</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hassel</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Jagus</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gutierrez</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Kalvakolanu</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid</article-title>
          <source>Mol Cell Biol</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>6493</fpage>
          <lpage>6504</lpage>
          <!--PubMed citation query: 'Mol Cell Biol||18|6493||bib22|'-->
          <pub-id pub-id-type="pmid">9774665</pub-id>
        </citation>
      </ref>
      <ref id="bib23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Ponniah</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lufei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I</article-title>
          <source>Mol Cell Biol</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>8447</fpage>
          <lpage>8456</lpage>
          <!--PubMed citation query: 'Mol Cell Biol||24|8447||bib23|'-->
          <pub-id pub-id-type="pmid">15367666</pub-id>
        </citation>
      </ref>
      <ref id="bib24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hwang</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Shong</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation</article-title>
          <source>Mol Endocrinol</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>1155</fpage>
          <lpage>1166</lpage>
          <!--PubMed citation query: 'Mol Endocrinol||17|1155||bib24|'-->
          <pub-id pub-id-type="pmid">12637586</pub-id>
        </citation>
      </ref>
      <ref id="bib25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katoh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Harach</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Solitary, multiple, and familial oxyphil tumours of the thyroid gland</article-title>
          <source>J Pathol</source>
          <year>1998</year>
          <volume>186</volume>
          <fpage>292</fpage>
          <lpage>299</lpage>
          <!--PubMed citation query: 'J Pathol||186|292||bib25|'-->
          <pub-id pub-id-type="pmid">10211119</pub-id>
        </citation>
      </ref>
      <ref id="bib26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimura</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Nikiforova</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Knauf</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Nikiforov</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Fagin</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>1454</fpage>
          <lpage>1457</lpage>
          <!--PubMed citation query: 'Cancer Res||63|1454||bib26|'-->
          <pub-id pub-id-type="pmid">12670889</pub-id>
        </citation>
      </ref>
      <ref id="bib27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Endonuclease G is an apoptotic DNase when released from mitochondria</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>412</volume>
          <fpage>95</fpage>
          <lpage>99</lpage>
          <!--PubMed citation query: 'Nature||412|95||bib27|'-->
          <pub-id pub-id-type="pmid">11452314</pub-id>
        </citation>
      </ref>
      <ref id="bib28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jemmerson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome <italic>c</italic></article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>86</volume>
          <fpage>147</fpage>
          <lpage>157</lpage>
          <!--PubMed citation query: 'Cell||86|147||bib28|'-->
          <pub-id pub-id-type="pmid">8689682</pub-id>
        </citation>
      </ref>
      <ref id="bib29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lufei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Novotny-Diermayr</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ong</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction</article-title>
          <source>EMBO J</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>1325</fpage>
          <lpage>1335</lpage>
          <!--PubMed citation query: 'EMBO J||22|1325||bib29|'-->
          <pub-id pub-id-type="pmid">12628925</pub-id>
        </citation>
      </ref>
      <ref id="bib30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MÃ¡ximo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cameselle-Teijeiro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors</article-title>
          <source>Am J Pathol</source>
          <year>2002</year>
          <volume>160</volume>
          <fpage>1857</fpage>
          <lpage>1865</lpage>
          <!--PubMed citation query: 'Am J Pathol||160|1857||bib30|'-->
          <pub-id pub-id-type="pmid">12000737</pub-id>
        </citation>
      </ref>
      <ref id="bib31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MÃ¡ximo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance</article-title>
          <source>Virchows Arch</source>
          <year>2000a</year>
          <volume>437</volume>
          <fpage>107</fpage>
          <lpage>115</lpage>
          <!--PubMed citation query: 'Virchows Arch||437|107||bib31|'-->
          <pub-id pub-id-type="pmid">10993269</pub-id>
        </citation>
      </ref>
      <ref id="bib32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MÃ¡ximo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial DNA âcommon' deletion in Hurthle cell lesions of the thyroid</article-title>
          <source>J Pathol</source>
          <year>2000b</year>
          <volume>192</volume>
          <fpage>561</fpage>
          <lpage>562</lpage>
          <!--PubMed citation query: 'J Pathol||192|561||bib32|'-->
          <pub-id pub-id-type="pmid">11113879</pub-id>
        </citation>
      </ref>
      <ref id="bib33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nesland</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sambade</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Johannessen</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry</article-title>
          <source>Ultrastruct Pathol</source>
          <year>1985</year>
          <volume>8</volume>
          <fpage>269</fpage>
          <lpage>290</lpage>
          <!--PubMed citation query: 'Ultrastruct Pathol||8|269||bib33|'-->
          <pub-id pub-id-type="pmid">4082297</pub-id>
        </citation>
      </ref>
      <ref id="bib34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Haura</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Turkson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sinibaldi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Coppola</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Heller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Karras</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bromberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pardoll</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jove</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis</article-title>
          <source>Oncogene</source>
          <year>2002</year>
          <volume>21</volume>
          <fpage>2000</fpage>
          <lpage>2008</lpage>
          <!--PubMed citation query: 'Oncogene||21|2000||bib34|'-->
          <pub-id pub-id-type="pmid">11960372</pub-id>
        </citation>
      </ref>
      <ref id="bib35">
        <citation citation-type="book"><person-group person-group-type="author"><name><surname>Rosai</surname><given-names>J</given-names></name><name><surname>Carcangiu</surname><given-names>ML</given-names></name><name><surname>DeLellis</surname><given-names>RA</given-names></name></person-group><article-title>Tumours of the thyroid gland</article-title><source>Atlas of Tumour Pathology</source><year>1992</year><publisher-name>Washington: Armed Forces Institute of Pathology</publisher-name>3rd series, Armed Forces Institute of Pathology (ed)</citation>
      </ref>
      <ref id="bib36">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wynford-Thomas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms</article-title>
          <source>J Pathol</source>
          <year>1998</year>
          <volume>185</volume>
          <fpage>71</fpage>
          <lpage>78</lpage>
          <!--PubMed citation query: 'J Pathol||185|71||bib36|'-->
          <pub-id pub-id-type="pmid">9713362</pub-id>
        </citation>
      </ref>
      <ref id="bib37">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Trovisco</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Preto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>MÃ¡ximo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Botelho</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Seruca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC</article-title>
          <source>Oncogene</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>4578</fpage>
          <lpage>4580</lpage>
          <!--PubMed citation query: 'Oncogene||22|4578||bib37|'-->
          <pub-id pub-id-type="pmid">12881714</pub-id>
        </citation>
      </ref>
      <ref id="bib38">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tumours of thyroid: a brief overview with emphasis on the most controversial issues</article-title>
          <source>Curr Diag Pathol</source>
          <year>1995</year>
          <volume>2</volume>
          <fpage>15</fpage>
          <lpage>22</lpage>
          <!--PubMed citation query: 'Curr Diag Pathol||2|15||bib38|'-->
        </citation>
      </ref>
      <ref id="bib39">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sobrinho-SimÃµes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nesland</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sambade</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Johannessen</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry</article-title>
          <source>Ultrastruct Pathol</source>
          <year>1985</year>
          <volume>8</volume>
          <fpage>131</fpage>
          <lpage>142</lpage>
          <!--PubMed citation query: 'Ultrastruct Pathol||8|131||bib39|'-->
          <pub-id pub-id-type="pmid">4060255</pub-id>
        </citation>
      </ref>
      <ref id="bib40">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugg</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Ezzat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Asa</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1998</year>
          <volume>83</volume>
          <fpage>4116</fpage>
          <lpage>4122</lpage>
          <!--PubMed citation query: 'J Clin Endocrinol Metab||83|4116||bib40|'-->
          <pub-id pub-id-type="pmid">9814501</pub-id>
        </citation>
      </ref>
      <ref id="bib41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tallini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ladanyi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosai</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jhanwar</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors</article-title>
          <source>Cytogenet Cell Genet</source>
          <year>1994</year>
          <volume>66</volume>
          <fpage>253</fpage>
          <lpage>259</lpage>
          <!--PubMed citation query: 'Cytogenet Cell Genet||66|253||bib41|'-->
          <pub-id pub-id-type="pmid">7909283</pub-id>
        </citation>
      </ref>
      <ref id="bib42">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trovisco</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Vieira de Castro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maximo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Magalhaes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abrosimov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guiu</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Sobrinho-Simoes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>BRAF mutations are associated with some histological types of papillary thyroid carcinoma</article-title>
          <source>J Pathol</source>
          <year>2004</year>
          <volume>202</volume>
          <fpage>247</fpage>
          <lpage>251</lpage>
          <!--PubMed citation query: 'J Pathol||202|247||bib42|'-->
          <pub-id pub-id-type="pmid">14743508</pub-id>
        </citation>
      </ref>
      <ref id="bib43">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yeh</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Lunetta</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>van Orsouw</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>FD</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Mutter</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Vijg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dahia</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Eng</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>2060</fpage>
          <lpage>2066</lpage>
          <!--PubMed citation query: 'Oncogene||19|2060||bib43|'-->
          <pub-id pub-id-type="pmid">10803467</pub-id>
        </citation>
      </ref>
      <ref id="bib44">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Tininini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bromberg</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Poli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Kalvakolanu</surname>
              <given-names>DV</given-names>
            </name>
          </person-group>
          <article-title>The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2003</year>
          <volume>100</volume>
          <fpage>9342</fpage>
          <lpage>9347</lpage>
          <!--PubMed citation query: 'Proc Natl Acad Sci USA||100|9342||bib44|'-->
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Electropherograms showing <italic>GRIM-19</italic> mutations in case 4 (<bold>A</bold> â mutated sequence, <bold>B</bold> â wild-type sequence), case 5 (<bold>C</bold> â mutated sequence, <bold>D</bold> â wild-type sequence), case 6 (<bold>E</bold> â mutated sequence, <bold>F</bold> â wild-type sequence) and case 7 (<bold>G</bold> â mutated sequence, <bold>H</bold> â wild-type sequence). The mutated nucleotides are indicated by the arrow. For details see <xref rid="tbl2" ref-type="table">Table 2</xref>.</p>
      </caption>
      <graphic mime-subtype="jpeg" xlink:href="92-6602547f1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>Histology of <italic>GRIM-19</italic> mutated tumours. <bold>A</bold> and <bold>B</bold> â HÃ¼rthle cell lesions from case 5 presenting GRIM-19 germline mutations (<bold>A</bold> â HÃ¼rthle cell adenoma; <bold>B</bold> â HÃ¼rthle cell variant of papillary carcinoma). (<bold>C</bold>) HÃ¼rthle cell variant of follicular carcinoma (case 4) displaying somatic GRIM-19 mutation. (<bold>D</bold>) HÃ¼rthle cell variant of papillary carcinoma (case 7) presenting a somatic <italic>GRIM-19</italic> mutation and a ret/PTC-1 rearrangement.</p>
      </caption>
      <graphic mime-subtype="jpeg" xlink:href="92-6602547f2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>Alignment of the GRIM-19 protein sequence in four species (<italic>Homo sapiens</italic>, <italic>Bos taurus</italic>, <italic>Mus musculus</italic> and <italic>Xenopus tropicalis</italic>; accession number: NP_057049, NP_788845, NP_075801 and NP_988900, respectively). Arrows indicate the positions of the amino acids mutated in our series of HÃ¼rthle cell tumours (see <xref rid="tbl2" ref-type="table">Table 2</xref>).</p>
      </caption>
      <graphic mime-subtype="jpeg" xlink:href="92-6602547f3"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p content-type="table-title">Primer sequences used in GRIM-19 amplification and sequencing</p>
      </caption>
      <table frame="hsides" rules="groups" border="1" width="85%">
        <colgroup>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">Â </th>
            <th align="left" valign="top" charoff="50">
              <bold>Primer sequence (5â²-3â²)<sup>a</sup></bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>Exon-1</italic>
            </td>
            <td align="left" valign="top" charoff="50">GCA ACA CCC CAG AGG CAA GGT GA</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">AGA CTC TGA GAC CCC GGC GCA</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">Â </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>Exon-2</italic>
            </td>
            <td align="left" valign="top" charoff="50">CAG TGT CCC CTG ATT GCA GAC</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">ACT TTC AGA CAA CGC CCA CCA</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">Â </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>Exon-3</italic>
            </td>
            <td align="left" valign="top" charoff="50">GGT CTG ACC TGA GTG TGG GTT</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">CTT CCG GCC AGT GAC CTC CCA</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">Â </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>Exon-4</italic>
            </td>
            <td align="left" valign="top" charoff="50">AGG CTT GAA GGG GTG CTA CTA</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">TCT GCC GTG GCT GGC ACC TCT</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">Â </td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">
              <italic>Exon-5</italic>
            </td>
            <td align="left" valign="top" charoff="50">GGT GGC TGT GCC TCT ACC CAT</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" charoff="50">AAA GGG GGT CAG GGG TCC TTT</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tbfnote1">
          <label>a</label>
          <p>For each exon, the first oligonucleotide represents the forward primer, and the second corresponds to the reverse primer.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <p content-type="table-title">Summary of the data on the four cases with <italic>GRIM-19</italic> mutations</p>
      </caption>
      <table frame="hsides" rules="groups" border="1" width="85%">
        <colgroup>
          <col align="left"/>
          <col align="char" char="."/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">
              <bold>Case</bold>
            </th>
            <th align="char" valign="top" char="." charoff="50">
              <bold>Age (years)</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Diagnosis</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Nucleotide alteration</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Protein alteration</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">4</td>
            <td align="char" valign="top" char="." charoff="50">42</td>
            <td align="left" valign="top" charoff="50">HCFC</td>
            <td align="left" valign="top" charoff="50">C77T</td>
            <td align="left" valign="top" charoff="50">A26V</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">5</td>
            <td align="char" valign="top" char="." charoff="50">60</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">G264C</td>
            <td align="left" valign="top" charoff="50">K88N</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">6</td>
            <td align="char" valign="top" char="." charoff="50">33</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">A247G</td>
            <td align="left" valign="top" charoff="50">S83G</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">7</td>
            <td align="char" valign="top" char="." charoff="50">32</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">G593C</td>
            <td align="left" valign="top" charoff="50">R198P</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tbfnote2">
          <label/>
          <p>HCFC=HÃ¼rthle cell variant of follicular carcinoma, HCPC=HÃ¼rthle cell variant of papillary carcinoma.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl3" position="float">
      <label>Table 3</label>
      <caption>
        <p content-type="table-title">Summary of the data on <italic>ICAM1</italic> relative expression in the four cases with <italic>GRIM-19</italic> mutations</p>
      </caption>
      <table frame="hsides" rules="groups" border="1" width="85%">
        <colgroup>
          <col align="left"/>
          <col align="char" char="."/>
          <col align="left"/>
          <col align="char" char="Â±"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">
              <bold>Case</bold>
            </th>
            <th align="char" valign="top" char="." charoff="50">
              <bold>Age (years)</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Diagnosis</bold>
            </th>
            <th align="char" valign="top" char="Â±" charoff="50">
              <bold><italic>ICAM1</italic> expression<sup>a</sup> Tumour tissue <italic>vs</italic> normal tissue</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">4</td>
            <td align="char" valign="top" char="." charoff="50">42</td>
            <td align="left" valign="top" charoff="50">HCFC</td>
            <td align="char" valign="top" char="Â±" charoff="50">3.2Â±0.4</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">5</td>
            <td align="char" valign="top" char="." charoff="50">60</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="char" valign="top" char="Â±" charoff="50">4.1Â±0.1</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">6</td>
            <td align="char" valign="top" char="." charoff="50">33</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="char" valign="top" char="Â±" charoff="50">3.3Â±0.3</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">7</td>
            <td align="char" valign="top" char="." charoff="50">32</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="char" valign="top" char="Â±" charoff="50">5.0Â±0.3</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tbfnote3">
          <label/>
          <p>HCFC=HÃ¼rthle cell variant of follicular carcinoma, HCPC=HÃ¼rthle cell variant of papillary carcinoma.</p>
        </fn>
        <fn id="tbfnote4">
          <label>a</label>
          <p>Values are expressed as the ratio between the expressions of <italic>ICAM1</italic> in tumoural tissues <italic>vs</italic> normal tissue, in meanÂ±s.d. (after three measurements per case).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl4" position="float">
      <label>Table 4</label>
      <caption>
        <p content-type="table-title">Summary of the data regarding ret/PTC rearrangements and <italic>B-RAF</italic> mutations in the four patients with <italic>GRIM-19</italic> mutations</p>
      </caption>
      <table frame="hsides" rules="groups" border="1" width="85%">
        <colgroup>
          <col align="left"/>
          <col align="char" char="."/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
        </colgroup>
        <thead valign="bottom">
          <tr>
            <th align="left" valign="top" charoff="50">
              <bold>Case</bold>
            </th>
            <th align="char" valign="top" char="." charoff="50">
              <bold>Age (years)</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>Diagnosis</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold><italic>B-RAF</italic> mutation</bold>
            </th>
            <th align="left" valign="top" charoff="50">
              <bold>RET/PTC rearrangements</bold>
            </th>
          </tr>
        </thead>
        <tbody valign="top">
          <tr>
            <td align="left" valign="top" charoff="50">4</td>
            <td align="char" valign="top" char="." charoff="50">42</td>
            <td align="left" valign="top" charoff="50">HCFC</td>
            <td align="left" valign="top" charoff="50">Negative</td>
            <td align="left" valign="top" charoff="50">Negative</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">5</td>
            <td align="char" valign="top" char="." charoff="50">60</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">Negative</td>
            <td align="left" valign="top" charoff="50">Negative</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">6</td>
            <td align="char" valign="top" char="." charoff="50">33</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">Not done</td>
            <td align="left" valign="top" charoff="50">Not done</td>
          </tr>
          <tr>
            <td align="left" valign="top" charoff="50">7</td>
            <td align="char" valign="top" char="." charoff="50">32</td>
            <td align="left" valign="top" charoff="50">HCPC</td>
            <td align="left" valign="top" charoff="50">Negative</td>
            <td align="left" valign="top" charoff="50">Positive</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tbfnote5">
          <label/>
          <p>HCFC=HÃ¼rthle cell variant of follicular carcinoma, HCPC=HÃ¼rthle cell variant of papillary carcinoma.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-wrap>
</article>

</metadata></record></GetRecord></OAI-PMH>